Hanmi Pharm. Co., Ltd.

KOSE:A128940 Stock Report

Market Cap: ₩3.4t

Hanmi Pharm Balance Sheet Health

Financial Health criteria checks 6/6

Hanmi Pharm has a total shareholder equity of ₩1,245.0B and total debt of ₩494.4B, which brings its debt-to-equity ratio to 39.7%. Its total assets and total liabilities are ₩1,971.1B and ₩726.1B respectively. Hanmi Pharm's EBIT is ₩260.0B making its interest coverage ratio 12.1. It has cash and short-term investments of ₩200.2B.

Key information

39.7%

Debt to equity ratio

₩494.40b

Debt

Interest coverage ratio12.1x
Cash₩200.22b
Equity₩1.24t
Total liabilities₩726.14b
Total assets₩1.97t

Recent financial health updates

Does Hanmi Pharm (KRX:128940) Have A Healthy Balance Sheet?

Nov 01
Does Hanmi Pharm (KRX:128940) Have A Healthy Balance Sheet?

Hanmi Pharm (KRX:128940) Seems To Use Debt Rather Sparingly

Jun 11
Hanmi Pharm (KRX:128940) Seems To Use Debt Rather Sparingly

Hanmi Pharm (KRX:128940) Use Of Debt Could Be Considered Risky

Feb 16
Hanmi Pharm (KRX:128940) Use Of Debt Could Be Considered Risky

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Hanmi Pharm. Co., Ltd. (KRX:128940)

Nov 19
Risks To Shareholder Returns Are Elevated At These Prices For Hanmi Pharm. Co., Ltd. (KRX:128940)

Does Hanmi Pharm (KRX:128940) Have A Healthy Balance Sheet?

Nov 01
Does Hanmi Pharm (KRX:128940) Have A Healthy Balance Sheet?

Does Hanmi Pharm (KRX:128940) Deserve A Spot On Your Watchlist?

Oct 17
Does Hanmi Pharm (KRX:128940) Deserve A Spot On Your Watchlist?

Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 36% Below Their Intrinsic Value Estimate

Aug 16
Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 36% Below Their Intrinsic Value Estimate

Pinning Down Hanmi Pharm. Co., Ltd.'s (KRX:128940) P/E Is Difficult Right Now

Jul 31
Pinning Down Hanmi Pharm. Co., Ltd.'s (KRX:128940) P/E Is Difficult Right Now

Do Hanmi Pharm's (KRX:128940) Earnings Warrant Your Attention?

Jul 16
Do Hanmi Pharm's (KRX:128940) Earnings Warrant Your Attention?

Hanmi Pharm (KRX:128940) Seems To Use Debt Rather Sparingly

Jun 11
Hanmi Pharm (KRX:128940) Seems To Use Debt Rather Sparingly

A Look At The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)

May 08
A Look At The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)

Hanmi Pharm. Co., Ltd.'s (KRX:128940) Share Price Not Quite Adding Up

Apr 22
Hanmi Pharm. Co., Ltd.'s (KRX:128940) Share Price Not Quite Adding Up

Calculating The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)

Mar 15
Calculating The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)

Hanmi Pharm (KRX:128940) Use Of Debt Could Be Considered Risky

Feb 16
Hanmi Pharm (KRX:128940) Use Of Debt Could Be Considered Risky

What Percentage Of Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Do Insiders Own?

Jan 17
What Percentage Of Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Do Insiders Own?

Hanmi Pharm's (KRX:128940) Stock Price Has Reduced 48% In The Past Five Years

Dec 22
Hanmi Pharm's (KRX:128940) Stock Price Has Reduced 48% In The Past Five Years

Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 22% Below Their Intrinsic Value Estimate

Nov 24
Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 22% Below Their Intrinsic Value Estimate

Financial Position Analysis

Short Term Liabilities: A128940's short term assets (₩721.5B) exceed its short term liabilities (₩623.5B).

Long Term Liabilities: A128940's short term assets (₩721.5B) exceed its long term liabilities (₩102.6B).

Debt to Equity History and Analysis

Debt Level: A128940's net debt to equity ratio (23.6%) is considered satisfactory.

Reducing Debt: A128940's debt to equity ratio has reduced from 100.7% to 39.7% over the past 5 years.

Debt Coverage: A128940's debt is well covered by operating cash flow (45.1%).

Interest Coverage: A128940's interest payments on its debt are well covered by EBIT (12.1x coverage).

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 15:47
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hanmi Pharm. Co., Ltd. is covered by 33 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dae Woong YooBookook Securities Co. Ltd
Seohyun LeeCitigroup Inc
Hyonseok KimCLSA